Immunoconjugates: current status and future potential.

M Eaton

doi:10.1080/1061186021000038067

Home/Archive/PubMed

PubMed · 12683718

Immunoconjugates: current status and future potential.

M Eaton

View original source ↗Export metadata ↓

Abstract

Whilst the concepts involved in immunoconjugates go back two centuries to the ideas of Ehrlich; it was only in the early 1980s that biotechnology gave us the tools to make pure immunoconjugates, in quantities sufficient for clinical studies [Garnett, M.C. (2002) "Targeted drug conjugates: principles and progress". Advanced Drug Delivery Reviews, 53, 171-216]. The early problems with immunogenicity that antibodies encountered in the clinic were addressed, in part by chimeric antibodies and later with humanised antibodies. At this time a number of different approaches were seriously evaluated for immunoconjugates, all with significant industrial backing, particularly from the emerging biotechnology companies.

Explore related subjects

Drug Delivery Systems Drug Industry Humans Immunoconjugates Toxins, Biological Editorial

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

M Eaton. 2002. Immunoconjugates: current status and future potential.. https://doi.org/10.1080/1061186021000038067

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase.

The synthesis and abl tyrosine kinase inhibitory activities of alkyltriazenes conjugated to phenylaminopyrimidines are described. Significant abl inhibitory activities were observed only when a benzamido spacer was inserted between the 1,2,3-triazene chain and the 2-phenyaminopyridopyrimidine moiety.

Drug Delivery Systems↗

PubMed2003

NMR-based screening technologies.

NMR-based ligand screening is now an established field in its own right. In recent years, advances in both methodology and hardware have broadened its range of applications and pushed back practical limitations, leading to the growing importance of NMR screening as a tool in industrial drug research. An overview of new screening methods and applications is presented here, and ways in which NMR-screening is being used in cooperation with other screening techniques are discussed.

Drug Delivery Systems↗

PubMed2003

G protein-coupled receptor microarrays for drug discovery.

The dominance of G protein-coupled receptors (GPCRs) as a drug target class, coupled with the increased pace of target identification and expansion of compound libraries, presents a compelling need to develop technologies to screen multiple GPCRs simultaneously. To address this need, GPCR microarrays that require the co-immobilization of lipid molecules and the probe receptors of interest have been fabricated, using conventional robotic printing technologies. Assays to screen compounds for their pharmacological properties (binding affinity, relative potency and selectivity) using GPCR microarrays are discussed.

Drug Delivery Systems↗